Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001

• Luca L.G. Janssen,
• Theresia M. Westers,
• Jeroen Rovers,
• Peter J.M. Valk,
• Jacqueline Cloos,
• Tanja D. de Gruijl,
• Arjan A. van de Loosdrecht

Affiliations

Luca L.G. Janssen

1 Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands

Theresia M. Westers

1 Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands

Jeroen Rovers

3 Mendus AB, R&D Center, Leiden, The Netherlands

Peter J.M. Valk

4 Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands

Jacqueline Cloos

1 Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands

Tanja D. de Gruijl

2 Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands

Arjan A. van de Loosdrecht

1 Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands